Phase 3 Graft-Versus-Host Disease Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
Allogeneic Hematopoietic Cell TransplantGraft-Versus-Host Disease
Shanghai Jiao Tong University School of Medicine316 enrolled1 locationNCT06705062
Recruiting
Phase 3
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Graft-Versus-Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.182 enrolled41 locationsNCT06682169
Recruiting
Phase 2Phase 3
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Graft-Versus-Host DiseaseBone Marrow Transplant ComplicationsImmunologic Suppression+2 more
Hospital Israelita Albert Einstein50 enrolled1 locationNCT03818334